文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

病例报告:嵌合抗原受体 T 细胞治疗后急性淋巴细胞白血病患者出现局部细胞因子释放综合征:一种可能的模型、文献回顾与展望。

Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.

机构信息

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

出版信息

Front Immunol. 2021 Jul 19;12:707191. doi: 10.3389/fimmu.2021.707191. eCollection 2021.


DOI:10.3389/fimmu.2021.707191
PMID:34349766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8326907/
Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable clinical efficacy in treatment of many malignancies especially for B-cell hematologic malignancies. However, the application of CAR-T cells is hampered by potentially adverse events, of which cytokine release syndrome (CRS) is one of the severest and the most studied. Local cytokine-release syndrome (L-CRS) at particular parts of the body has been reported once in a while in B-cell lymphoma or other compartmental tumors. The underlying mechanism of L-CRS is not well understood and the existing reports attempting to illustrate it only involve compartmental tumors, some of which even indicated L-CRS only happens in compartmental tumors. Acute lymphoblastic leukemia (ALL) is systemic and our center treated a B-cell ALL patient who exhibited life threatening dyspnea, L-CRS was under suspicion and the patient was successfully rescued with treatment algorithm of CRS. The case is the firstly reported L-CRS related to systemic malignancies and we tentatively propose a model to illustrate the occurrence and development of L-CRS of systemic malignancies inspired by the case and literature, with emphasis on the new recognition of L-CRS.

摘要

嵌合抗原受体 T(CAR-T)细胞疗法在治疗许多恶性肿瘤方面,尤其是 B 细胞血液恶性肿瘤方面,已取得显著的临床疗效。然而,CAR-T 细胞的应用受到潜在不良事件的限制,其中细胞因子释放综合征(CRS)是最严重和研究最多的一种。偶尔在 B 细胞淋巴瘤或其他隔室肿瘤中也会报道局部细胞因子释放综合征(L-CRS)。L-CRS 的潜在机制尚不清楚,现有的试图说明它的报告仅涉及隔室肿瘤,其中一些甚至表明 L-CRS 仅发生在隔室肿瘤中。急性淋巴细胞白血病(ALL)是全身性的,我们中心治疗了一位患有危及生命的呼吸困难的 B 细胞 ALL 患者,怀疑发生了 L-CRS,并通过 CRS 治疗方案成功抢救了患者。该病例是首例与系统性恶性肿瘤相关的 L-CRS 报告,我们受此病例和文献启发,暂拟了一个模型来阐述系统性恶性肿瘤 L-CRS 的发生和发展,重点是对 L-CRS 的新认识。

相似文献

[1]
Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.

Front Immunol. 2021

[2]
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.

J Cell Mol Med. 2021-12

[3]
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.

Adv Ther. 2019-8-19

[4]
Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.

Medicine (Baltimore). 2021-5-14

[5]
Management of cytokine release syndrome related to CAR-T cell therapy.

Front Med. 2019-9-28

[6]
Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.

Clin Cancer Res. 2018-10-15

[7]
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.

Front Immunol. 2021

[8]
Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots.

Expert Opin Pharmacother. 2024-8

[9]
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol. 2019-3-18

[10]
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.

Cancer Immunol Immunother. 2024-4-17

引用本文的文献

[1]
A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.

Clin Pharmacol. 2025-4-29

[2]
Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy.

Oxf Med Case Reports. 2025-1-18

[3]
Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review.

Ann Hematol. 2025-3

[4]
Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series.

J Clin Exp Hematop. 2024

[5]
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.

Sci Adv. 2024-5-10

[6]
CT Demonstration of Local Cytokine-Release Syndrome Involving the Head and Neck Following Chimeric Antigen Receptor T Cell Infusion Therapy.

Korean J Radiol. 2024-4

[7]
Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Cureus. 2023-5-11

[8]
Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review).

Oncol Lett. 2023-5-16

[9]
Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022-4-25

[10]
Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia.

Case Rep Oncol. 2022-3-15

本文引用的文献

[1]
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

Stem Cell Investig. 2021-1-15

[2]
Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications.

J Adv Pract Oncol. 2020-3

[3]
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.

Clin Cancer Res. 2021-6-1

[4]
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

J Immunother Cancer. 2020-12

[5]
Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.

Front Immunol. 2020

[6]
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.

Signal Transduct Target Ther. 2020-7-29

[7]
Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.

Leukemia. 2020-6-27

[8]
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Blood. 2019-12-12

[9]
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.

Am J Hematol. 2019-2-18

[10]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索